Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Agios Pharma (AGIO)
NASDAQ:AGIO
Agios Pharma (AGIO) Stock Price & Analysis
543 Followers
AGIO Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$19.80 - $35.50
Previous Close$33
Volume506.07K
Average Volume (3M)776.78K
Market Cap
$1.87B
Enterprise Value$1.17B
Total Cash (Recent Filing)$776.93M
Total Debt (Recent Filing)$72.00M
Price to Earnings (P/E)-5.2
Beta1.22
Next Earnings
Aug 01, 2024EPS Estimate
-$1.6Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.31
Shares Outstanding56,772,966
10 Day Avg. Volume718,711
30 Day Avg. Volume776,785
Standard Deviation0.14
R-Squared0.10
Alpha-0.00856
Financial Highlights & Ratios
Price to Book (P/B)2.27
Price to Sales (P/S)69.68
Price to Cash Flow (P/CF)-6.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue43.57
Enterprise Value/Gross Profit48.81
Enterprise Value/Ebitda-3.44
Forecast
1Y Price Target
$43.40Price Target Upside31.52% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Agios Pharma News
Bulls Say, Bears Say
Bulls Say
Product SalesPyrukynd sales show a significant increase, highlighting the drug's growing acceptance and demand in the market.
Regulatory MilestonesManagement's narrowed guidance for the ENERGIZE-T data readout supports the potential for a broad thalassemia label, enhancing the drug's market scope.
Strategic PartnershipsThe company's pursuit of global commercialization partnerships for Pyrukynd targets key regions, expanding its market presence in areas with high disease prevalence.
Bears Say
EarningsPyrukynd sales of $7.1mn missed consensus by approximately 10%, indicating a decline in revenue.
Financial PerformanceAGIO reported Q4 results with Pyrukynd sales below expectations and a significant net loss.
Product DemandThe company attributed the lower sales to reduced customer inventory levels, suggesting potential issues in product demand or supply chain management.
---
Ownership Overview
37.44% Insiders
34.56% Mutual Funds
26.39% Other Institutional Investors
1.61% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
AGIO FAQ
What was Agios Pharma’s price range in the past 12 months?
Agios Pharma lowest stock price was $19.80 and its highest was $35.50 in the past 12 months.
What is Agios Pharma’s market cap?
Currently, no data Available
When is Agios Pharma’s upcoming earnings report date?
Agios Pharma’s upcoming earnings report date is Aug 01, 2024 which is in 82 days.
How were Agios Pharma’s earnings last quarter?
Agios Pharma released its earnings results on May 02, 2024. The company reported -$1.45 earnings per share for the quarter, beating the consensus estimate of -$1.648 by $0.198.
Is Agios Pharma overvalued?
According to Wall Street analysts Agios Pharma’s price is currently Undervalued.
Does Agios Pharma pay dividends?
Agios Pharma does not currently pay dividends.
What is Agios Pharma’s EPS estimate?
Agios Pharma’s EPS estimate is -$1.6.
How many shares outstanding does Agios Pharma have?
Agios Pharma has 56,772,964 shares outstanding.
What happened to Agios Pharma’s price movement after its last earnings report?
Agios Pharma reported an EPS of -$1.45 in its last earnings report, beating expectations of -$1.648. Following the earnings report the stock price went up 2.733%.
Which hedge fund is a major shareholder of Agios Pharma?
Among the largest hedge funds holding Agios Pharma’s share is Farallon Capital Management, L.L.C.. It holds Agios Pharma’s shares valued at 93M.
---
Agios Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$43.40 (31.52% Upside)
$43.40 (31.52% Upside)
Blogger Sentiment
Bullish
AGIO Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 1.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $4.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.5%
Last 30 Days ▲ 8.1%
Last 30 Days ▲ 8.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
27.90%
12-Months-Change
Fundamentals
Return on Equity
-39.61%
Trailing 12-Months
Asset Growth
-26.20%
Trailing 12-Months
Company Description
Agios Pharma
Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.
---
AGIO Company Deck
---
AGIO Earnings Call
Q1 2024
0:00 / 0:00
---
AGIO Stock 12 Month Forecast
Average Price Target
$43.40
▲(31.52% Upside)
Technical Analysis
Crispr Therapeutics AG
―
Bluebird Bio
―
Crinetics Pharmaceuticals
―
Nektar Therapeutics
―
Best Analysts Covering AGIO
1 Year
1 Year Success Rate
7/9 ratings generated profit
1 Year Average Return
+23.69%
reiterated a buy rating 3 months ago
Copying Greg Harrison's trades and holding each position for 1 Year would result in 77.78% of your transactions generating a profit, with an average return of +23.69% per trade.
---